Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
The FDA has greenlit Novo's oral formulation of Wegovy (semaglutide) for the treatment of patients who are obese or overweight with weight-related medical problems. The once-daily pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease. Shares in the Copenhagen-listed drugmaker rose 5% to DKr320.00 ($50.40) at market open on 23 December, compared to a market close of DKr 303.50 on 22 December. Novo has a market cap of DKr1.449tn ($230bn), making it one of the most valuable companies in Europe. Though oral semaglutide was first approved in 2019 under the brand name Rybelsus, this was for type 2 diabetes only, meaning oral Wegovy is the first oral GLP-1RA for the treatment of obesity in the US. Novo expects to launch the tablet in early January 2026, with manufacturing already underway at its North Carolina facilities – a site which rece
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk's weight-loss challenge in five charts [Yahoo! Finance]Yahoo! Finance
- Novo's Wegovy pill to test demand from consumers with cash [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo's Wegovy pill to test demand from consumers with cash [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Says Eli Lilly's GLP-1 Pill Is “Going to Revolutionize Everything” [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- LLY's page on the SEC website